{"name": "Rexahn Pharmaceuticals",
 "permalink": "rexahn-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/rexahn-pharmaceuticals",
 "homepage_url": "http://www.rexahn.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@rexahn.com",
 "phone_number": "240-268-5300",
 "description": "",
 "created_at": "Thu Sep 16 04:35:10 UTC 2010",
 "updated_at": "Thu Sep 16 04:35:47 UTC 2010",
 "overview": "\u003Cp\u003ERexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its drug candidates in Phase II clinical trials include Archexin, the lead anticancer drug candidate is an inhibitor of the protein kinase Akt for the treatment of pancreatic cancer and renal cell carcinoma; Serdaxin for the treatment of depression and neurodegenerative disorders; and Zoraxel, a drug for sexual dysfunction that modulates the sexual activity control center in the brain. Its pre-clinical pipeline products include RX-1792, a molecule targeted anticancer drug candidate; RX-5902, a molecule microtubule inhibitor anticancer drug candidate; RX-3117, a molecule anti-metabolite nucleoside anticancer drug candidate; RX-8243, a molecule aurora kinase inhibitor anticancer drug candidate; RX-0201-Nano, nanoliposomal anticancer Akt-1 inhibitor; RX-0047-Nano, nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101 \u0026amp; RX-21202, a nano-polymer anticancer. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; and Revaax Pharmaceuticals LLC. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       50],
      "assets/images/resized/0010/1943/101943v1-max-150x150.jpg"],
     [[156,
       52],
      "assets/images/resized/0010/1943/101943v1-max-250x250.jpg"],
     [[156,
       52],
      "assets/images/resized/0010/1943/101943v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO \u00e2\u20ac\u201c Founder and Chairman",
    "person":
     {"first_name": "Chang",
      "last_name": "H. Ahn",
      "permalink": "chang-h-ahn",
      "image": null}},
   {"is_past": false,
    "title": "President and COO",
    "person":
     {"first_name": "Rick",
      "last_name": "Soni",
      "permalink": "rick-soni",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "15245 Shady Grove Road",
    "address2": "Suite 455",
    "zip_code": "20850",
    "city": "Rockville",
    "state_code": "MD",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NYSE:RNN"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}